Disease on EC 1.3.1.22 - 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5alpha-reductase activity in the prostate.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
5-Alpha-reductase type 2 deficiency. A new case in the Spanish population.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
A novel mutation of the 5alpha-reductase type 2 gene in two unrelated Egyptian children with ambiguous genitalia.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Accuracy of Urinary Etiocholanolone/Androsterone Ratio as Alternative to Serum Testosterone/Dihydrotestosterone Ratio for Diagnosis of 5 Alpha-reductase Type 2 Deficiency Patients and Carriers in Indonesia.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Androgens, androgen receptors, and male gender role behavior.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Detection of the G34R mutation in the 5 alpha reductase 2 gene by allele specific PCR and its linkage to the 89L allele among Egyptian cases.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Fetal Genotype-Phenotype Sex Discordance: A Case of 5-Alpha-Reductase Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular basis of androgen insensitivity.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
New Territory for an Old Disease: 5-Alpha-Reductase Type 2 Deficiency in Bulgaria.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Testicular histological and immunohistochemical aspects in a post-pubertal patient with 5 alpha-reductase type 2 deficiency: case report and review of the literature in a perspective of evaluation of potential fertility of these patients.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
[The importance of DNA analysis in the diagnosis of steroid 5-alpha-reductase deficiency]
Adenocarcinoma
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Adenocarcinoma
Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.
Alopecia
5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro.
Alopecia
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Azoospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Breast Neoplasms
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Breast Neoplasms
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
Breast Neoplasms
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
Carcinoma
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Carcinoma, Transitional Cell
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Coloboma
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Dermatitis
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Dermatitis, Atopic
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Disorder of Sex Development, 46,XY
5 alpha-reduced androgens play a key role in murine parturition.
Disorder of Sex Development, 46,XY
5-alpha-reductase 2 deficiency in a woman with primary amenorrhea.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2).
Disorder of Sex Development, 46,XY
Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme.
Dwarfism
5alpha-Reductase activity in Lycopersicon esculentum: cloning and functional characterization of LeDET2 and evidence of the presence of two isoenzymes.
Endometriosis
Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis.
Hyperprolactinemia
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
Hypospadias
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
Hypospadias
Expression of the androgen receptor and 5 alpha-reductase type 2 in the developing human fetal penis and urethra.
Hypospadias
Steroid 5alpha-reductase 1 polymorphisms and testosterone/dihydrotestosterone ratio in male patients with hypospadias.
Hypospadias
Two novel mutations of SRD5A2 gene in Indonesian siblings with clinical 5-alpha-reductase deficiency.
Insulin Resistance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Neoplasms
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
Neoplasms
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Neoplasms
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Neoplasms
Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue.
Neoplasms
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Neoplasms
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Neoplasms
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Neoplasms
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Neoplasms
SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.
Neoplastic Processes
Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
Oligospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Optic Atrophy
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Ovarian Neoplasms
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Peripheral Arterial Disease
Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease.
Prostatic Hyperplasia
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Establishment of a novel model for studying the effects of extracts of Chinese herb medicine on human type II 5alpha-reductase in vitro.
Prostatic Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Prostatic Neoplasms
A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
Prostatic Neoplasms
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
Prostatic Neoplasms
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Prostatic Neoplasms
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Prostatic Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Prostatic Neoplasms
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Prostatic Neoplasms
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Prostatic Neoplasms
Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.
Prostatic Neoplasms
Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
Prostatic Neoplasms
SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.
Prostatic Neoplasms
The role of molecular genetics in chemoprevention studies of prostate cancer.
Retinal Dystrophies
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
html completed